Company · CIK 0001520262 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Alkermes plc. · ALKS
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 SForm 4 → | Sep 3, 6:32 pm EDT | David Joseph GaffinEVP, CLO, Alkermes, Inc. | 2,034 | $48.01 | $97,652 | 223,422 | −0.90% | 10b5-1 |
| Sep 1, 2026 SForm 4 → | Sep 1, 7:08 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 9,000 | $46.99 | $422,874 | 65,389 | −12.1% | 10b5-1 |
| Sep 1, 2026 MForm 4 → | Sep 1, 7:08 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | $24.59 | $122,950 | 74,389 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 MForm 4 → | Sep 1, 7:08 pm EDT | Craig C. HopkinsonEVP R&D, Chief Medical Officer | 5,000 | — | — | 61,276 | — | 10b5-1 |